About Life Edit
Gene editing without limits
Our Mission
To rewrite the future by curing disease, making any edit, anywhere.
Life Edit is ElevateBio’s business focused on advancing next-generation gene editing technologies and therapeutics. We have built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs), base editors, and reverse transcriptase (RT) editors, opening a new frontier of gene editing.
Our platform enables us to target any genomic sequence and potentially develop novel human therapeutics for the most challenging genetic diseases, including ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies.
How We Work
Life Edit is ElevateBio’s gene editing business. We are focused on driving innovation by offering our gene editing expertise to partners to discover and develop next-generation therapies.
Our full spectrum of editing modalities combined with ElevateBio’s end-to-end capabilities and technology platforms enables us to discover, develop, manufacture, and commercialize an unprecedented, broad spectrum of cell and gene therapies and regenerative medicines. Through a connected mission, we are committed to powering the creation of genetic medicines at a speed the world deserves.
The Life Edit Team
We are led by a world-class team of visionary scientists and leaders with proven expertise in genome editing, and the development of cell and gene therapies. We are guided by curiosity, scientific rigor, and integrity. We believe in discovery and unlimited potential. We care about science and the lives of patients.
Careers
If you’re inspired by our values of scientific excellence, boundless innovation, and leadership, we’d like to hear from you.
Partner with Life Edit
We are looking to form strategic partnerships with biotech and pharmaceutical companies to advance their life-changing and curative therapies. Our flexible partnership options span non-exclusive licensing of our gene editing systems, exclusive licenses to assets, and collaborations as starting points for strategic partnerships.
To provide access to genome editing tools and cure disease, we’re seeking partnerships with biotech and pharmaceutical companies including those interested in ex vivo therapies. We will also continue to support our broad portfolio of innovative biotech companies.
